Abstracts tagged "Myositis"

Abstract Number: 1090 • ACR Convergence 2020
Abnormal HDL Antioxidant Function Is Associated with Longitudinal Change in Lung Physiology in Dermatomyositis/Polymyositis Associated Lung Disease
Sangmee Bae¹, Jennifer Wang¹, Ani Shahbazian² and Christina Charles-Schoeman², ¹University of California Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with dermatomyositis (DM) and polymyositis (PM). We previously reported abnormal anti-oxidant function…
Abstract Number: 1989 • ACR Convergence 2020
NXP2 Autoantibodies Link to Interferon Signature in Juvenile Myositis Lesional Skin
Jessica Turnier¹, Lauren Pachman², Lori Lowe³, Alex Tsoi³, Sultan Elhaj¹, Rajasree Menon¹, Maria Amoruso², Gabrielle Morgan⁴, Johann Gudjonsson⁵, Celine Berthier³ and J Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Michigan, Ann Arbor, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Michigan, Ann ArborUniversity of Michigan
Background/Purpose: Skin inflammation can herald systemic disease in juvenile myositis (JM), yet we lack an understanding of pathogenic mechanisms driving skin inflammation in JM. The…
Abstract Number: 1069 • ACR Convergence 2020
Scleromyositis Is Associated with Nailfold Capillary Abnormalities Compared to Immune-Mediated Necrotizing Myopathy
Océane Landon-Cardinal¹, Valérie Leclair², Yves Troyanov³, Martial Koenig⁴, Alain Meyer⁵, Sabrina Hoa¹, Josiane Bourré-Tessier¹, Isabelle Ferdinand⁶, Jason Karamchandani⁷, Erin O'Ferrall⁸, Minoru Satoh⁹, Marvin Fritzler¹⁰, Benjamin Ellezam¹¹, Jean-Luc Senécal¹, Marie Hudson² and Geneviève Gyger², ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ⁴Division of Internal Medicine, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁵Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁶Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁷Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis associated with features of systemic sclerosis (SSc) and characterized by prominent vasculopathic features on ultrastructural…
Abstract Number: 1091 • ACR Convergence 2020
A Computer-Aided Diagnostic System for Quantitative Scoring of Extent of Interstitial Lung Disease (ILD) in Dermatomyositis/Polymyositis Associated ILD
Sangmee Bae¹, Andrea Oh², Grace Kim³, Jonathan Goldin³ and Christina Charles-Schoeman⁴, ¹University of California Los Angeles, Los Angeles, CA, ²National Jewish Health, Denver, CO, ³University of California, Los Angeles, Los Angeles, ⁴University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) occurs in up to 80% of patients with dermatomyositis (DM) and polymyositis (PM), and is a leading cause of morbidity…
Abstract Number: 1990 • ACR Convergence 2020
Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Lylan Bergeron², Samantha Dill², Michelle O'Brien², Laura Vian³, Minal Jain⁴, Manuk Manukyan², Xiaobai Li⁵, Shajia Lu³, Wanxia L. Tsai³, Kalyani Mishra Thakur⁶, Yinghui Shi⁶, Massimo Gadina⁷, April Brundidge², Michelle Millwood², Lisa G. Rider⁸ and Robert Colbert², ¹Juvenile Myositis Pathogenesis and Therapeutics Unit / NIAMS / National Institutes of Health, Bethesda, MD, ²Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ³Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁴Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁵Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, ⁶Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 0085 • ACR Convergence 2020
Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition
Fadi Charouf¹, Netanel Karbian¹, Itamar Altman¹, Yakov Fellig¹ and Dror Mevorach¹, ¹Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…
Abstract Number: 1070 • ACR Convergence 2020
Scleromyositis Is Associated with Distinct Muscle Vasculopathic Features
Océane Landon-Cardinal¹, Valérie Leclair², Yves Troyanov³, Alain Meyer⁴, Sabrina Hoa¹, Josiane Bourré-Tessier¹, Valérie Nadon⁵, Julie Drouin⁶, Jason Karamchandani⁷, Erin O'Ferrall⁸, Minoru Satoh⁹, Marvin Fritzler¹⁰, Jean-Luc Senécal¹, Marie Hudson² and Benjamin Ellezam¹¹, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ⁴Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁵Division of Rheumatology, Hôpital Notre-Dame, Montreal, Québec, Canada, Montréal, QC, Canada, ⁶Division of Rheumatology, Centre hospitalier régional de Trois-Rivières, Trois-Rivières, QC, Canada, ⁷Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis (AIM) associated with features of systemic sclerosis (SSc). Muscle biopsy studies are sparse and have…
Abstract Number: 1092 • ACR Convergence 2020
NMR-Based Serum Metabolomics, Is It Different in Clinico-Serological Clusters of Idiopathic Inflammatory Myositis?
Naveen R¹, Anupam Guleria², Dinesh Kumar², Umesh Kumar², Anamika Anuja¹, Vikas Agarwal³ and Latika Gupta⁴, ¹Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Centre of Biomedical Research, Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Post Graduate Institute of Medical Sciences, LUCKNOW, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Idiopathic inflammatory myositis (IIM) are rare and heterogenous. Myositis specific antibodies (MSA) show mutual exclusivity and identify specific clinical phenotypes1. Most biomarker studies are…
Abstract Number: 0451 • ACR Convergence 2020
Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis
Sophia Verspohl¹, Tobias Holderried¹, Charlotte Behning², Peter Brossart¹ and Valentin Schaefer³, ¹Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Institute for Medical Biometrics, Informatics and Epidemiology (IMBIE), University Hospital Bonn, Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ³Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Immune checkpoint inhibitors (ICIs) have improved cancer therapy [1] by inducing a higher immune system activity and subsequent attack of tumor cells. However, this effect…
Abstract Number: 1073 • ACR Convergence 2020
Anti Melanoma Differentiation-associated Protein Gene 5 Antibody Titer Monitoring Is a Useful Indicator for Early Detection of Recurrence in Rapidly Progressive Interstitial Lung Disease Associated with Dermatomyositis
Yuji Hosono¹, Azusa Kojima², Keigo Shimura², Akira Ishii², Yuto Izumi², Kazuki Hirano², Sho Sasaki², Takayoshi Kurabayashi², Noriko Sasaki², Chiho Yamada² and Shinji Sato², ¹Tokai University School of Medicine, Kanagawa, Japan, ²Tokai University School of Medicine, Isehara, Kanagawa, Japan
Background/Purpose: Anti melanoma differentiation-associated gene 5 (MDA5) antibody (Ab) positive dermatomyositis (DM) often complicates rapidly progressive interstitial lung disease (RP-ILD), which shows fatal prognosis at…
Abstract Number: 1093 • ACR Convergence 2020
Impact of Blood Flow Restricted Strength Training on Myogenic Stem Cells and Myofiber Hypertrophy in Sporadic Inclusion Body Myositis Patients
Kasper Yde Jensen¹, Henrik Daa Schrøder², Jakob Nielsen³, Mikkel Jacobsen³, Eleanor Boyle³, Anders Nørkær Jørgensen³, Rune Dueholm Bech⁴, Per Aagaard³ and Louise Pyndt Diederichsen¹, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ²Odense University Hospital, Odense, Denmark, ³University of Southern Denmark - Odense, Odense, Denmark, ⁴Zealand University Hospital, Copenhagen, Denmark
Background/Purpose: Sporadic inclusion body myositis (sIBM) is clinically characterised by marked progressive muscle weakness and impaired physical function. Physical training has become an area of…
Abstract Number: 0957 • ACR Convergence 2020
Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis
Bhargavi Duvvuri¹, Lauren Pachman², Richard Moore¹, Stephen Doty³ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL, ³The Hospital for Special Surgery, New York
Background/Purpose: Calcinosis, the accumulation of calcium crystals in soft tissues, is often a locus of infection and a debilitating manifestation of chronic juvenile dermatomyositis (JDM),…
Abstract Number: 1074 • ACR Convergence 2020
A Novel Autoantibody Recognizing a 65-kDa Protein Is Associated with Scleromyositis with Head Drop and/or Bent Spine
Karel Venne¹, Valérie Leclair², Julie D'Aoust¹, Océane Landon-Cardinal³, Alexandra Albert⁴, Julie Beauchemin⁵, Denis Brunet⁶, Lucie Roy⁷, Benjamin Ellezam⁸, Jason Karamchandani⁹, Rami Massie¹⁰, Erin O'Ferrall¹⁰, Alain Meyer¹¹, Yves Troyanov¹², Minoru Satoh¹³, Marvin Fritzler¹⁴ and Marie Hudson², ¹Division of Rheumatology, Rheumatology Fellow, McGill University,, Montreal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada, ⁵Division of Rheumatology, Hôpital Charles-Lemoyne, Longueuil, QC, Canada, ⁶Division of Neurology, Centre Hospitalier de l’Université Laval, Quebec, QC, Canada, ⁷Division of Rheumatology, CIUSSS du Saguenay Lac-Saint-Jean, Saguenay, Canada, ⁸Division of Pathology, CHU Sainte-Justine, Montreal, QC, Canada, ⁹Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ¹⁰Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ¹¹Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ¹²Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ¹³Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis associated with features of systemic sclerosis (SSc). There is a paucity of data on scleromyositis…
Abstract Number: 1095 • ACR Convergence 2020
Avascular Necrosis in the Hopkins Myositis Cohort: A Single Center Experience
Khalil Bourji¹, Christopher Mecoli², Julie Paik³, Jemima Albayda³, Eleni Tiniakou³, William Kelly³, Thomas E Lloyd³, Andrew Mammen⁴ and Lisa Christopher-Stine³, ¹Wayne State University/Henry Ford Hospital, Dearborn, MI, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴NIH, Bethesda, MD
Background/Purpose: To assess the prevalence of avascular necrosis (AVN) in a large cohort of patients with idiopathic inflammatory myopathies (IIM) and define the major associated…
Abstract Number: 0959 • ACR Convergence 2020
Altered Gut Microbiome in Dermatomyositis
Sangmee Bae¹, Tien Dong², Venu Lagishetty³, William Katzka⁴, Jonathan Jacobs³ and Christina Charles-Schoeman⁵, ¹University of California Los Angeles, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, ³University of California, Los Angeles, Los Angeles, ⁴UCLA, Los Angeles, ⁵University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Dermatomyositis (DM) is an autoimmune myopathy associated with marked microvascular dysfunction and high morbidity and mortality. The gut microbiome has been implicated in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].